Children with SMA1 will have limited movement, which means they can’t sit without support or walk. These symptoms begin a few months after birth and will get progressively worse. However, gene therapy and disease-modifying therapies for SMA1 offer hope. Research on Spinraza in infants with SMA1 shows many reaching developmental milestones like head control, rolling over, sitting, and standing. A small number of children were able to walk without support. With more therapies on the horizon, many of these children can live longer and without severe disease complications.